Altre lingue Pasithea Therapeutics Corp.

Azioni

KTTA

US70261F2020

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 05/07/2024			Variaz. 5gg	Var. 1 gen.
5,075 ^USD	-2,03%		+0,28%	-31,42%

13/06	Pasithea Therapeutics Corp. annuncia il completamento dell'arruolamento e del dosaggio iniziale della coorte 2, in seguito alla raccomandazione positiva del Comitato di Revisione della Sicurezza per PAS-004 nello studio clinico di Fase 1 in corso.	CI
14/05	Pasithea Therapeutics Corp. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial	13/06
Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial	13/06
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting	28/05
Pasithea Therapeutics : Shareholder Meeting - Form 8-K	14/05
Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting	29/04
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers	24/04
Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	24/04
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004	13/02
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004	13/02
Top Premarket Decliners	12/01
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004, Establishes Strengthened Intellectual Property Position	09/01
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	08/01
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	08/01
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients	02/01
Pasithea Therapeutics Gets FDA Acceptance for PAS-004 IND Application	02/01
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients	02/01
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients	02/01
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023	28/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Pasithea Therapeutics Corp.

Azioni

KTTA

US70261F2020

Altre lingue

Filtri